The medical journal Prescrire publishes every year its list of drugs deemed “more dangerous than useful”. This year, 106 drugs, including 88 marketed in France, are cited.
They are in your pharmacies and should be avoided because their benefits “are judged to be lower than the risks”. Like every year, the medical journal Prescrire highlights many common medications that consumers should avoid. In his investigation, published at the end of November, we found 88 drugs authorized on French soil and within the European Union.
Among the drugs appearing on this “black list”, the review mentions Smecta and its variants, prescribed in particular in cases of gastroenteritis. According to the authors of the study, these medicines made from clay should be avoided “because of their natural pollution by lead” which contains “neurological, hematological, renal and cardiovascular toxic effects“.
“Last chance” treatments singled out
Other medications to avoid, those used for sore throats or coughs such as Toplexil syrup or Maxilase exposing to “sometimes serious skin or allergic disorders“. Furthermore, the journal Prescrire denounces the conditions for resorting to certain so-called treatments “last chance” for patients suffering from serious pathologies such as Defitelio or Farydak in oncology.
Compared to the list published at the end of 2023, Fintepla – an amphetamine intended to combat severe forms of epilepsy in children – is making its return, notes BFMTV, in the list of drugs to be banned because it exposes people to “troubles neuropsychiques“and to various”cardiovascular disorders“.
The study – which addresses both “to patients” and “to caregiverss” – has the objective “to help them choose quality care and avoid putting them at disproportionate risk“, assure its authors. It thus highlights the “side effects“of certain medications, believing that certain effects”rare, but serious, may not have been detected during testing“.
published on December 6 at 3:26 p.m., Teddy Perez, 6Medias
Share
Health
